Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin.

Clinical Cancer Research · 3 Nov 2026 · Journal Article

Rodrigues, Al-Ahmadie + more

The abstract is read at the publisher; the summary is JClub's.

A composite biomarker combining membranous Nectin-4 expression with NECTIN4 gene amplification predicts response to enfortumab vedotin in muscle-invasive or metastatic urothelial cancer.

Why it matters: Platinum-based chemotherapy has been replaced as first-line therapy, but clinicians still need biomarkers to identify which patients will respond to enfortumab vedotin.
What they did: The study evaluated a composite biomarker that integrates membranous Nectin-4 levels with NECTIN4 gene amplification to forecast treatment response to enfortumab vedotin.
The result: The biomarker is predictive of response, supporting its use to guide enfortumab vedotin selection in patients with muscle-invasive or metastatic urothelial cancer.

AI summary of the abstract · may contain errors · not medical advice · read the paper.

Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.

Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.
Clinical Cancer Research · 9 Sept 2026 · Journal Article
Read it in JClub
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42714834
Open in JClub

Journals this month

All journals →

Topics moving, week to 13 Nov 2026

All topics →

By field

All journals by field →

Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin.

Related in JClub

Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

Browse JClub